KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Mao, Chen ^a,b   Zhou, Junhua ^a   Yang, Zuyao ^b   Huang, Yafang ^b   Wu, Xinyin ^b   Shen, Hong ^a   Tang, Jinling ^b   Chen, Qing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CHINESE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; CHINA; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY;

CHINA; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS;

EID: 84860617477     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036653     Document Type: Article

References (38)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 351: 337-345.
2. Meyerhardt JA, Mayer RJ, (2005) Systemic Therapy for Colorectal Cancer. N Engl J Med 352: 476-487.
3. Van Cutsem E, Peeters M, Siena S, Humblet Y, et al. (2007) Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology 25: 1658-1664.
4. Tol J, Punt C, (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 32: 437-53.
5. Schrag D, (2004) The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351: 317-319.
6. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu DS, et al. (2007) Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine 357: 2040-2048.
7. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies. Cancer Research 67: 2643-2648.
8. Freeman D, Juan T, Reiner M, Hecht JR, Meropol, et al. (2008) Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7: 184-190.
9. Food and Drug Administration (2011) Class Labeling Changes to Anti-EGFR Monoclonal Antibodies, Cetuximab (Erbitux) and Panitumumab (Vectibix): KRAS Mutations. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm Accessed 07 October2011.
10. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu DS, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
11. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. The Lancet Oncology 6: 279-286.
12. Molinari F, Martin V, Saletti P, Saletti P, De Dosso S, et al. (2009) Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100: 1087-1094.
13. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, et al. (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
14. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, et al. (2009) PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies. Cancer Research 69: 1851-1857.
15. Shen H, Yuan Y, Hu H, Zhong X, Ye XX, et al. (2011) Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol 17: 809-816.
16. Liou JM, Wu MS, Shun CT, Chiu HM, Chen MJ, et al. (2011) Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis 6: 1387-1395.
17. Li HT, Lu YY, An YX, Wang X, Zhao QC, (2011) KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 25: 1691-1697.
18. Vaughn C, Zobell S, Furtado L, Baker CL, Samowitz WSet, (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50: 307-12.
19. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A, (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-62.
20. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu DS, et al. (2010) Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA: The Journal of the American Medical Association 304: 1812-1820.
21. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, et al. (2010) Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted Oncology 5: 19-28.
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 11: 753-762.
23. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T, (2010) Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer doi:10.1038/sj.bjc.6606008.
24. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, et al. (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. European Journal of Cancer 46: 1997-2009.
25. Li W, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, et al. (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5: 2.
26. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, et al. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.
27. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, et al. (1994) Phosphatidylinositol-3-OH kinase direct target of Ras. Nature 370: 527-532.
28. Bardelli A, Siena S, (2010) Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer. Journal of Clinical Oncology 28: 1254-1261.
29. Li H, Lu Y, An Y, Wang X, Zhao QC, (2011) KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 25: 1691-1697.
30. Huang WF, Peng LY, Jiang JK, Li X, Chen L, (2010) PIK3CA mutations and expressions status of PTEN in Guangxi Zhuang populations colorectal cancer and their relationship. Med J Chin PAPF 21: 925-929.
31. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL, (2011) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol doi:10.1093/annonc/mdr464.
32. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, et al. (2005) Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers. Clinical Cancer Research 11: 2875-2878.
33. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, et al. (2009) PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology 27: 2622-2629.
34. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, et al. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2 4: e7287.
35. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, et al. (2009) Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. Journal of Clinical Oncology 27: 5924-5930.
36. He X, He X, Zheng J, (2009) Expressions of CD44v6 and PTEN in colorectal cancer and correlation study. (in Chinese). Modern Practical Medcine 21: 698-699.
37. Lu X, Qi G, Yang Z, (2009) Expression of CDX2,PTEN,Ki-67 and their correlativity of DNA ploidy in colorectal carcinoma(in Chinese). Cancer Research and Clinic 21: 588-90,596.
38. Negri F, Bozzetti C, Lagrasta C, Crafa P, et al. (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102: 162-164.